Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.

Xiang DongZewu ZhangQin ZhangLu ChenGuangtai CaoChen LiuTianqiang SongWei LuWei Zhang

Published in: Journal of cancer research and clinical oncology (2022)

In patients with advanced BTCs, the combination of GemOX plus sintilimab and lenvatinib or NGS-guided targeted therapy showed promising ORR and DCR, especially for the patients with positive PD-L1 expression and targetable gene alterations.

Keyphrases

genome wide
copy number
stem cells
dna methylation
bone marrow
transcription factor
cell therapy